Role of oncogenic signalling in epigenetics and DNA repair

Positions held

  • Since 2009: Group Leader, University Medical Center, Mainz
  • Since 2009: Assistant Professor, University Medical Center, Mainz
  • Since 2008: Attending Physician, Department of Hematology and Oncology, University Medical Center, Mainz
  • 2005-2008: Postdoc, Harvard Medical School, Boston, USA

Education

  • 1994-1998: Medical Thesis, Institute of Immunology, LMU Munich
  • 1997: Medical License, LMU Munich

Most relevant publications by Thomas Kindler

Sasca D, Hähnel PS, Szybinski J, Khawaja K, Kriege O, Pante SV, Bullinger L, Strand S, Strand D, Theobald M and Kindler T (2014). SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood, 124, 121-133

Hähnel PS, Enders B, Sasca D, Roos WP, Kaina B, Bullinger L, Theobald M and Kindler T (2014). Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy. Blood, 123, 2355-2366

Hartwell KA, Miller PG, Mukherjee S, Kahn AR, Stewart AL, Logan DJ, Negri JM, Duvet M, Järås M, Puram R, Dancik V, Al-Shahrour F, Kindler T, Tothova Z, Chattopadhyay S, Hasaka T, Narayan R, Dai M, Huang C, Shterental S, Chu LP, Haydu JE, Shieh JH, Steensma DP, Munoz B, Bittker JA, Shamji AF, Clemons PA, Tolliday NJ, Carpenter AE, Gilliland DG, Stern AM, Moore MA, Scadden DT, Schreiber SL, Ebert BL and Golub TR (2013). Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol, 9, 840-848

Krönke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik VI, Kühn MW, Rücker FG, Holzmann K, Paschka P, Kapp-Schwörer S, Späth D, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk RF, Döhner H and Döhner K (2013). Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood, 122, 100-108

Tam WF, Hähnel P, Schüler A, Lee BH, Okabe R, Zhu N, Pante S, Raffel G, Mercher T, Wernig G, Bockamp E, Kreft A, Robinson GW, Hennighausen L, Gilliland DG and Kindler T (2013). STAT5 is crucial for the maintenance of leukemic stem cells in MOZ-TIF2 induced acute myeloid leukemogenesis. Cancer Res, 73, 373-384

Breitenbuecher F, Markova B, Kasper S, Carius B, Stauder T, Schnittger S, Haferlach T, Boehmer F, Huber C, Kindler T* and Fischer T* (2009). Rewired FLT3_ITD Signaling Pathways Confer Primary Resistance to FLT3-Kinase Inhibitors in Acute Myeloid Leukemia. Blood, 113, 4063-4073 

Mercher T, Cornejo MG, Sears C, KindlerT, Moore SA, Aster JC and Gilliland DG (2008). Notch signaling specifies megakaryocyte development. Cell Stem Cell, 3, 314-326

Kindler T, Cornejo MG, Scholl C, Liu J, Leeman DS, Haydu JE, Fröhling S, Lee BH and Gilliland DG (2008). KRasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to γ-secretase inhibitors. Blood, 112, 3373-3382

Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer SD, Gratwohl A, Choudhary CR, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen PS, Huber C and Fischer T (2005). Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood, 105, 335-340

Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, Duyster J, Peschel C, Kirkpatrick CJ, Theobald M, Gschaidmeier H, Huber C and Fischer T 2004). Efficacy and safety of imatinib in adult patients with ckit- positive acute myeloid leukemia. Blood, 103, 3644-3654

* indicates equal contribution

  Research website